• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然和合成类黄酮对胰高血糖素样肽-1 受体信号的调节。

Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.

机构信息

Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia.

出版信息

J Pharmacol Exp Ther. 2011 Feb;336(2):540-50. doi: 10.1124/jpet.110.176362. Epub 2010 Nov 12.

DOI:10.1124/jpet.110.176362
PMID:21075839
Abstract

The glucagon-like peptide 1 receptor (GLP-1R) is a promising target for the treatment of type II diabetes mellitus because of its role in metabolic homeostasis. In recent years, difficulties with peptide therapies have driven the search for small-molecule compounds to modulate the activity of this receptor. We recently identified quercetin, a naturally occurring flavonoid, as a probe-dependent, pathway-selective allosteric modulator of GLP-1R-mediated signaling. Using Chinese hamster ovary cells expressing the human GLP-1R, we have now extended this work to identify the structural requirements of flavonoids to modify GLP-1R binding and signaling (cAMP formation and intracellular Ca(2+) mobilization) of each of the GLP-1R endogenous agonists, as well as the clinically used exogenous peptide mimetic exendin-4. This study identified a chemical series of hydroxyl flavonols with the ability to selectively augment calcium (Ca(2+)) signaling in a peptide agonist-specific manner, with effects only on truncated GLP-1 peptides [GLP-1(7-36)NH(2) and GLP-1(7-37)] and exendin-4, but not on oxyntomodulin or full-length GLP-1 peptides [GLP-1(1-36)NH(2) and GLP-1(1-37)]. In addition, the 3-hydroxyl group on the flavone backbone (i.e., a flavonol) was essential for this activity, however insufficient on its own, to produce the allosteric effects. In contrast to hydroxyl flavonols, catechin had no effect on peptide-mediated Ca(2+) signaling but negatively modulated peptide-mediated cAMP formation in a probe-dependent manner. These data represent a detailed examination of the action of different flavonoids on peptide agonists at the GLP-1R and may aid in the development of future small molecule compounds targeted at this receptor.

摘要

胰高血糖素样肽 1 受体 (GLP-1R) 是治疗 2 型糖尿病的有前途的靶点,因为它在代谢稳态中发挥作用。近年来,由于肽疗法的困难,人们一直在寻找能够调节该受体活性的小分子化合物。我们最近发现,槲皮素是一种天然存在的类黄酮,是一种依赖探针的、途径选择性的 GLP-1R 介导信号的别构调节剂。使用表达人 GLP-1R 的中国仓鼠卵巢细胞,我们现在已经扩展了这项工作,以确定类黄酮的结构要求,以修饰每种 GLP-1R 内源性激动剂(GLP-1(7-36)NH2 和 GLP-1(7-37))和临床使用的外源性肽模拟物 exendin-4 的 GLP-1R 结合和信号转导(cAMP 形成和细胞内 Ca2+动员)。这项研究确定了一系列具有选择性增强肽激动剂特异性钙 (Ca2+) 信号能力的羟基黄酮醇化学系列,其作用仅对截断的 GLP-1 肽 [GLP-1(7-36)NH2 和 GLP-1(7-37)] 和 exendin-4 有效,但对 oxyntomodulin 或全长 GLP-1 肽 [GLP-1(1-36)NH2 和 GLP-1(1-37)] 无效。此外,黄酮骨架上的 3-羟基(即黄酮醇)对于这种活性是必不可少的,但仅凭自身不足以产生别构效应。与羟基黄酮醇相反,儿茶素对肽介导的 Ca2+信号没有影响,但以探针依赖的方式负调节肽介导的 cAMP 形成。这些数据代表了对不同类黄酮在 GLP-1R 上对肽激动剂作用的详细研究,可能有助于开发针对该受体的未来小分子化合物。

相似文献

1
Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.天然和合成类黄酮对胰高血糖素样肽-1 受体信号的调节。
J Pharmacol Exp Ther. 2011 Feb;336(2):540-50. doi: 10.1124/jpet.110.176362. Epub 2010 Nov 12.
2
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.胰高血糖素样肽 1 受体 (GLP-1R) 的变构配体以一种途径选择性的方式差异调节内源性和外源性肽的反应:对药物筛选的影响。
Mol Pharmacol. 2010 Sep;78(3):456-65. doi: 10.1124/mol.110.065664. Epub 2010 Jun 14.
3
Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.内源性激动剂胰高血糖素样肽-1(GLP-1)-(7-36)酰胺和小分子正变构调节剂“化合物 2”在 GLP-1 受体上的比较作用。
J Pharmacol Exp Ther. 2010 Sep 1;334(3):795-808. doi: 10.1124/jpet.110.166009. Epub 2010 May 27.
4
Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.氨基酸取代对参与肽活性和小分子变构的人胰高血糖素样肽-1 受体关键残基的影响差异。
J Pharmacol Exp Ther. 2015 Apr;353(1):52-63. doi: 10.1124/jpet.114.220913. Epub 2015 Jan 28.
5
Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.截短的胰高血糖素样肽-1与艾塞那肽α-芋螺毒素pl14a肽嵌合体保持效力和α-螺旋结构,并揭示体外cAMP信号传导至关重要的相互作用。
J Biol Chem. 2016 Jul 22;291(30):15778-87. doi: 10.1074/jbc.M116.724542. Epub 2016 May 10.
6
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.人胰高血糖素样肽-1 受体 (GLP-1R) 的第二细胞外环差异调节正位激动剂结合和功能,但不调节变构激动剂结合和功能。
J Biol Chem. 2012 Feb 3;287(6):3659-73. doi: 10.1074/jbc.M111.309369. Epub 2011 Dec 6.
7
Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.小分子变构调节胰高血糖素样肽-1 受体增强了胆囊收缩素对胰岛素的促分泌作用。
Mol Pharmacol. 2012 Dec;82(6):1066-73. doi: 10.1124/mol.112.080432. Epub 2012 Aug 28.
8
New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.使用胰高血糖素样肽-1(9-36)酰胺鉴定胰高血糖素样肽-1受体变构调节剂的新筛选策略及分析
Anal Biochem. 2015 Dec 15;491:23-30. doi: 10.1016/j.ab.2015.08.026. Epub 2015 Sep 2.
9
Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.人胰高血糖素样肽-1 受体(GLP-1R)功能的多态性和配体依赖性变化:别构拯救功能丧失突变。
Mol Pharmacol. 2011 Sep;80(3):486-97. doi: 10.1124/mol.111.072884. Epub 2011 May 26.
10
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.人胰高血糖素样肽-1 受体 (GLP-1R) 的第二细胞外环在 GLP-1 肽结合和受体激活中起关键作用。
J Biol Chem. 2012 Feb 3;287(6):3642-58. doi: 10.1074/jbc.M111.309328. Epub 2011 Dec 6.

引用本文的文献

1
Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system.口服抗糖尿病药物对肾素-血管紧张素-醛固酮系统的影响。
Eur J Clin Pharmacol. 2025 Jun;81(6):801-813. doi: 10.1007/s00228-025-03830-w. Epub 2025 Apr 1.
2
Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art.GLP-1 类似物与糖尿病环境中的自噬:最新进展。
Curr Diabetes Rev. 2024;20(10):e250124226181. doi: 10.2174/0115733998276570231222105959.
3
Benefits of GLP-1 Mimetics on Epicardial Adiposity.GLP-1 拟似物对心外膜脂肪的益处。
Curr Med Chem. 2023;30(37):4256-4265. doi: 10.2174/0929867330666230113110431.
4
Effects of Sambiloto () on GLP-1 and DPP-4 Concentrations between Normal and Prediabetic Subjects: A Crossover Study.匙羹藤对正常人和糖尿病前期患者体内胰高血糖素样肽-1(GLP-1)和二肽基肽酶-4(DPP-4)浓度的影响:一项交叉研究
Evid Based Complement Alternat Med. 2022 Jan 15;2022:1535703. doi: 10.1155/2022/1535703. eCollection 2022.
5
The Impact of Incretin-Based Medications on Lipid Metabolism.基于肠促胰岛素的药物对脂代谢的影响。
J Diabetes Res. 2021 Dec 29;2021:1815178. doi: 10.1155/2021/1815178. eCollection 2021.
6
Boosting GLP-1 by Natural Products.天然产物促进 GLP-1。
Adv Exp Med Biol. 2021;1328:513-522. doi: 10.1007/978-3-030-73234-9_36.
7
Impact of Incretin-Based Therapies on Adipokines and Adiponectin.基于肠促胰岛素的治疗对脂肪因子和脂联素的影响。
J Diabetes Res. 2021 Oct 7;2021:3331865. doi: 10.1155/2021/3331865. eCollection 2021.
8
Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.基于肠促胰岛素的治疗在糖尿病中的肾脏保护作用。
Biomed Res Int. 2021 Aug 21;2021:8163153. doi: 10.1155/2021/8163153. eCollection 2021.
9
The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂对糖尿病患者血压和心血管并发症的影响。
J Diabetes Res. 2021 Jun 30;2021:6518221. doi: 10.1155/2021/6518221. eCollection 2021.
10
Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.基于肠促胰岛素的药物的抗氧化潜力:分子机制综述。
Oxid Med Cell Longev. 2021 Apr 27;2021:9959320. doi: 10.1155/2021/9959320. eCollection 2021.